EGFR and lung carcinoma: The progressive better understanding of EGFR mutations in mNSCLC has allowed to set up the Lung Cancer Molecular Markers Graded Prognostic Assessment (Lung-mol-GPA based on EGFR status as the main target combined with other clinical parameters (25) to help clinical decisions on newly diagnosed with BM (see Table 1).